Infectious Diseases Department, IRCCS San Raffaele Scientific Institute & Vita-Salute University.
Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan.
AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188.
: We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.
我们评估了包含多替拉韦（DTG）和未增强的阿扎那韦（uATV）的两药方案在 151 例 HIV-RNA 超过 50 拷贝/ml 的 HIV-1 感染患者中的疗效和安全性。在中位随访 62（42-97）周期间，发生了 2 例病毒学失败（1%）和 13 例治疗中断（9%）；48 周时病毒学失败的概率为 0.8%（95%置信区间 0.2-5.6%）。对于长期接受抗逆转录病毒治疗和心血管疾病风险的个体，换用 DTG+uATV 可能代表一种增效和不使用转录酶逆转抑制剂的选择。
